Efforts at value-based care focus on patients’ needs

Original Source What is the value of a treatment? As of July, the U.S. government has given out close to 600 million doses of COVID-19 vaccines at prices that ranged between $15-$20 per dose, which means they spent $10-$12 billion on shots. Research shows that, as of March, the U.S. vaccination program saved 2 million lives and $900 billion in…

Read More

Price Controls Would Devastate Drug Development, Patient Access, Says New Analysis

Original Source: https://vitaltransformation.com/2022/07/build-back-better-act-total-market-impact-of-price-controls-in-medicare-parts-d-and-b/ Build Back Better Act Total market impact of price controls in Medicare parts D and B The Executive Summary The Build Back Better Act (BBBA) is designed to allow the US Government to ‘negotiate’ pricing under a set framework of reductions based upon the amount of time a drug has spent on…

Read More

New Funding Opportunity from the NIH: Small Business Transition Grant For Early Career Scientists

The National Cancer Institute (NCI) recently released a new funding opportunity for biotech companies and university researchers! The new Small Business Transition Grant funds the translation of technology from university to small business, as well as the transition of early career researchers from academia to industry. This award uses the Small Business Technology Transfer (STTR)…

Read More

PE-backed Angstrom Technology pursues acquisitions to fill cleanroom market gaps

Original Source WALKER — A couple of recent strategic acquisitions should further prepare cleanroom designer and builder Angstrom Technology Ltd. for overseas projects as the company continues a private equity-backed string of acquisitions. After New York City private equity firm ASGARD Partners & Co. acquired a controlling interest in Angstrom in November 2020, Angstrom has persued deals to expand…

Read More

FDA Urges Companies to be ’Recall Ready’ to Protect Public Health as Part of Final Guidance for Voluntary Recalls

Original Source Today, the U.S. Food and Drug Administration finalized guidance to help companies prepare to quickly and effectively remove violative products from the market. The guidance describes steps companies should take, before a recall is necessary, to develop recall policies and procedures that include training, planning and record-keeping to reduce the time a recalled…

Read More

U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis

CIBINQO is a once-daily oral treatment with proven efficacy to manage symptoms for adults who have not yet found relief with current options NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved CIBINQO® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of…

Read More

Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA

With pediatric COVID-19 cases surpassing 10 million and at the request of the FDA, the companies have submitted available data on the safety and efficacy of two 3 µg doses as part of a three-dose primary series for this age group to address the urgent public health need Companies plan to submit additional data on…

Read More

Opinion: Biden risks killing his cancer moonshot on the launchpad

Original Source For personal and political reasons, I strongly supported Joe Biden for president. He never wavered on climate change, women’s rights, immigration or other issues I care about. Paul Hastings is CEO of Nkarta Therapeutics in San Francisco and chairman of the Biotechnology Innovation Organization, a biotech trade group. Perhaps most compelling, though, was his…

Read More

Neogen, 3M announce blockbuster merger to create ‘global leader’ in food safety

Original Source Lansing-based food and animal safety products manufacturer Neogen Corp. plans to combine with conglomerate 3M’s food safety business. The two companies say they signed a definitive agreement for a deal to create a new global food safety and security company valued at $9.3 billion. Shareholders at Neogen (Nasdaq: NEOG) would hold about 49.9 percent of the…

Read More

FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year

Original Source   Ad hoc announcement pursuant to Art. 53 LR With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1 Leqvio provides effective and sustained LDL-C reduction of up to 52% vs. placebo for certain people with atherosclerotic cardiovascular disease (ASCVD) on…

Read More